Schlam et al. (2021) used it to profile the TME of primary and metastatic HER2+ breast cancer [18], discovering differences in immune cell infiltration and the expression of immune activation markers, with primary tumors showing enhanced immune cell infiltration within the stromal compartment compared with metastatic disease. Here, ERBB2 is linked to breast carcinoma.